1. Home
  2. TACT vs RNTX Comparison

TACT vs RNTX Comparison

Compare TACT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAct Technologies Incorporated

TACT

TransAct Technologies Incorporated

N/A

Current Price

$4.51

Market Cap

55.6M

Sector

Technology

ML Signal

N/A

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.34

Market Cap

50.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TACT
RNTX
Founded
1996
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.6M
50.9M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
TACT
RNTX
Price
$4.51
$0.34
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
24.9K
★ 899.0K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.16
EPS
★ 0.03
N/A
Revenue
N/A
N/A
Revenue This Year
$7.23
N/A
Revenue Next Year
$4.53
N/A
P/E Ratio
$154.33
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$0.28
52 Week High
$6.02
$2.10

Technical Indicators

Market Signals
Indicator
TACT
RNTX
Relative Strength Index (RSI) 40.75 24.57
Support Level $4.32 N/A
Resistance Level $5.42 $0.91
Average True Range (ATR) 0.29 0.07
MACD -0.07 -0.03
Stochastic Oscillator 17.39 15.43

Price Performance

Historical Comparison
TACT
RNTX

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: